3Billion

3Billion EBITDA per Share

The EBITDA per Share of 3Billion (394800.KQ) as of Oct 24, 2026 is -185.65 KRW. In the previous year, EBITDA per Share was -195.97 KRW — a change of -5.27% (higher).

EBITDA per Share

-185.65KRW

YoY

-5.27%

Last updated:

EBITDA per Share of 3Billion is 2025 -185.65 KRW. EBITDA per Share of 3Billion was 2024 -195.97 KRW. It decreases by -5.27% higher compared to the previous year.

The 3Billion EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2021
-213.02 KRW
Jan 1, 2022
-231.32 KRW
Jan 1, 2023
-220.27 KRW
Jan 1, 2024
-195.97 KRW
Jan 1, 2025
-185.65 KRW
The 3Billion EBITDA per Share history
YEAREBITDA per ShareYoY
-185.65KRW-5.27%
-195.97KRW-11.03%
-220.27KRW-4.77%
-231.32KRW+8.59%
-213.02KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

3Billion Stock analysis

What does 3Billion do? 3Billion Inc provides genetic testing services, focusing on rare genetic disease diagnostic testing. The company develops technology to automatically read the pathogenicity of genetic variants in the genome. Its primary products are diagnostic testing services and R&D technology for genetic variants. The target customers are medical institutions and healthcare providers requiring genetic diagnostics. The company operates in the healthcare sector, specifically in genetic diagnostics and research. 3Billion Inc's revenue comes from offering diagnostic testing services to healthcare facilities and licensing its R&D technology. The firm serves medical institutions seeking accurate genetic disease diagnosis and research institutions developing genetic analysis tools. The company's services support both clinical diagnostics and scientific research in genomics. The business model centers on two main revenue streams: direct sales of genetic diagnostic services and technology licensing. Healthcare providers purchase diagnostic testing to identify rare genetic conditions, while research organizations license the automatic pathogenicity reading technology for genomic studies. The company's focus on rare genetic diseases differentiates its offerings in the medical diagnostics market. 3Billion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3Billion stock

EBITDA per Share of 3Billion is -185.65 KRW in 2025.

EBITDA per Share of 3Billion changed from -195.97 KRW to -185.65 KRW, representing a -5.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share 3Billion since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — 3Billion

All Key Metrics — 3Billion